the product in the database has an inactive status
indications:
Relief of nose and eye symptoms associated with seasonal and chronic allergic rhinitis and symptoms of chronic idiopathic urticaria in adults and children aged ≥6 years.
Cetirizine - a metabolite of hydroxyzine, is a potent and selective antagonist of peripheral histamine H-receptors1. In addition, it has antiallergic activity, inhibits the influx of cells in the late phase of the inflammatory reaction - eosinophils, to the skin and conjunctiva. It inhibits the reaction leading to the formation of wheals and redness. It relieves the symptoms of rhinitis and does not affect lung function. The maximum steady-state cetirizine concentration occurs within 1.0 ± 0.5 hours after oral administration. Cetirizine is bound to plasma proteins in approximately 93 ± 0.3%. The first pass metabolism is not significantly affected. About 2/3 of the dose is excreted unchanged in the urine. Final T0,5 is about 10 hours; it is shorter in children.
Contraindications:
Hypersensitivity to Cetirizine, hydroxyzine, other piperazine derivatives or other components of the preparation. Severe renal impairment with creatinine clearance <10 ml / min. Due to the lactose content, do not use in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Precautions:
It is not recommended for use in children <6 years, because the pharmaceutical form (table on volume) does not allow for appropriate dose adjustment. Use with caution in patients with renal insufficiency (dose modification recommended), epilepsy or risk of seizures and in combination with alcohol.
Pregnancy and lactation:
Animal studies do not indicate a harmful effect of cetirizine on pregnancy, embryonal and / or fetal development, parturition and postnatal development. Caution should be exercised when cetirizine is administered to pregnant or breastfeeding women (the drug is excreted in human milk).
Side effects:
The following may occur: drowsiness, fatigue, headache and dizziness, abdominal pain, dry mouth, nausea, sore throat. In children with a frequency of ≥1%, diarrhea, drowsiness, rhinitis, and tiredness were observed. In addition, the following side effects have been reported post-marketing - uncommon: agitation, paresthesia, diarrhea, pruritus, rash, asthenia, malaise; rare: hypersensitivity reactions, aggressive behavior, confusion, depression, hallucinations, insomnia, movement disorders, tachycardia, abnormal liver function (increased transaminases, alkaline phosphatase, GGT, increased bilirubin), urticaria, edema, weight gain; very rare: thrombocytopenia, anaphylactic shock, tics, taste disturbances, syncope, tremor, dystonia, dyskinesia, accommodation disorder, blurred vision, eyeball rotation, angioneurotic edema, drug eruption, painful or difficult urination, involuntary urination; frequency unknown: amnesia, memory problems.
Dosage:
Orally. Adults and children> 12 years: 10 mg (1 table) once a day; children 6-12 years: 5 mg (1/2 times table) 2 times a day. In patients with hepatic impairment and in the elderly, no dosage adjustment is necessary. In adult patients with renal insufficiency, the dosage depends on the creatinine clearance (CCr) - CCr = 50-79 ml / min: 10 mg once a day; CCr = 30-49 ml / min: 5 mg once a day; CCr <30 ml / min: 5 mg every other day; CCr <10 ml / min, dialysis patients: do not use. In children with renal impairment, the dose should be determined individually based on the creatinine clearance, age and weight of the patient. The tablets should be swallowed with a glass of water. The tablets can be divided into halves along the incision.
(C)
